human dlat shrna silencing aav  (Vector Biolabs)

Journal: Molecular Therapy. Nucleic Acids

Article Title: A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics

doi: 10.1016/j.omtn.2026.102936

Figure Lengend Snippet: A workflow of this study (A) Overview of the mechanism of action of N-acetylgalactosamine-small interfering RNA (GalNAc-siRNA) and the seven approved GalNAc-SiRNA drugs collected in this study. (B) Schematic structure of the developed computational model for a GalNAc-siRNA. (C) Schematic workflow of the model informed GalNAc-siRNA development powered by the established computational platform.

Article Snippet: Finally, the platform was utilized to support the development of an investigational new angiotensinogen ( AGT )-silencing GalNAc-siRNA, termed SAL0132 (developed by Shenzhen Salubris Pharmaceuticals Co., Ltd), from preclinic rats and monkey to clinical studies.

Techniques: Small Interfering RNA

Journal: Neural Regeneration Research

Article Title: Lnc_011797 promotes ferroptosis and aggravates white matter lesions

doi: 10.4103/NRR.NRR-D-24-00676

Figure Lengend Snippet: Lnc_011797 regulates WNK1 expression in HUVECs. (A) RT-PCR analysis of lnc_011797 expression in HUVECs. (B) WNK1 mRNA expression after transfection with specific lentiviruses was analyzed via RT-PCR. The data were normalized to the control group. (C) Western blot analysis was used to assess WNK1 expression after transfection with specific lentiviruses. Data are expressed as mean ± SD ( n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 (one-way analysis of variance followed by the least significant difference post hoc tests). HUVECs: Human umbilical vein endothelial cells; RT-PCR: real-time polymerase chain reaction; WNK1: with-no-lysine (K) 1.

Article Snippet: Lnc_011797-overexpressing lentivirus (oe-lnc) and silencing lentivirus (si-lnc) were constructed by Genechem Co. Ltd. (Shanghai, China).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Transfection, Control, Western Blot, Real-time Polymerase Chain Reaction

Journal: Neural Regeneration Research

Article Title: Lnc_011797 promotes ferroptosis and aggravates white matter lesions

doi: 10.4103/NRR.NRR-D-24-00676

Figure Lengend Snippet: Lnc_011797 can bind to miR-193b-3p to regulate WNK1 expression. (A) Predicted binding sites between miR-193b-3p and lnc_011797 or WNK1. Lnc_011797 contains two predicted miR-193b-3p binding sites (shown in red). (B) RT-PCR analysis of miR-193b-3p expression in HUVECs transfected with the miR-193b-3p mimic, mimic control, miR-193b-3p inhibitor, or inhibitor control. (C, D) miR-193b-3p binding to lnc_011797 (C) and WNK1 (D) was confirmed by dual luciferase reporter gene assay. (E) Lnc_011797 regulates miR-193b-3p expression. (F-I) RT-PCR (F, G) and western blotting (H, I) were used to measure WNK1 expression in cells transfected with the lnc_011797–specific lentivirus and the miR-193b-3p mimic or inhibitor. The data were normalized to the control group. Data are expressed as mean ± SD ( n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 (one-way analysis of variance followed by the least significant difference post hoc tests). HUVECs: Human umbilical vein endothelial cells; RT-PCR: real-time polymerase chain reaction; WNK1: with-no-lysine (K) 1.

Article Snippet: Lnc_011797-overexpressing lentivirus (oe-lnc) and silencing lentivirus (si-lnc) were constructed by Genechem Co. Ltd. (Shanghai, China).

Techniques: Expressing, Binding Assay, Reverse Transcription Polymerase Chain Reaction, Transfection, Control, Luciferase, Reporter Gene Assay, Western Blot, Real-time Polymerase Chain Reaction